Mechanisms and Potential Treatment Options of Heart Failure in Patients With Multiple Myeloma.

Autor:	Proskuriakova E; Internal Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA., Jada K; Internal Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA., Kakieu Djossi S; Research, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA., Khedr A; Internal Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA., Neupane B; Internal Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA., Mostafa JA; Psychiatry, Psychotherapy and Research Field, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA.
Jazyk:	angličtina
Zdroj:	Cureus [Cureus] 2021 Jun 26; Vol. 13 (6), pp. e15943. Date of Electronic Publication: 2021 Jun 26 (Print Publication: 2021).
DOI:	10.7759/cureus.15943
Abstrakt:	Multiple myeloma is a pathology of plasma cells, with one of the most common side effects of its treatment is heart failure. In addition, cardiac amyloidosis could cause heart failure by itself. Even though mechanisms of cardiac amyloidosis are known, and they involve lysosomal dysfunction, reactive oxygen species (ROS) accumulation, and infiltrative effect by fibrils, there is no specific agent that could protect from these effects. While the molecular mechanism of doxorubicin cardiotoxicity via topoisomerase II β is established, the only FDA-approved agent for treatment is dexrazoxane. Liposomal doxorubicin can potentially improve response and decrease the development of heart failure due to microscopic liposomes that can accumulate and penetrate only tumor vasculature. Supplements that enhance mitochondrial biogenesis are also shown to improve doxorubicin-induced cardiotoxicity. Other agents, such as JR-311, ICRF-193, and ursolic acid, could potentially become new treatment options. Proteasome inhibitors, novel agents, have significantly improved survival rates among multiple myeloma patients. They act on a proteasome system that is highly active in cardiomyocytes and activates various molecular cascades in malignant cells, as well as in the heart, through nuclear factor kappa B (NF-kB), endoplasmic reticulum (ER), calcineurin-nuclear factor of activated T-cells (NFAT), and adenosine monophosphate-activated protein kinase (AMPKa)/autophagy pathways. Metformin, apremilast, and rutin have shown positive results in animal studies and may become a promising therapy as cardioprotective agents. This article aims to highlight the main molecular mechanisms of heart failure among patients with multiple myeloma and potential treatment options to facilitate the development and research of new preventive strategies. Hence, this will have a positive impact on life expectancy in patients with multiple myeloma. Competing Interests: The authors have declared that no competing interests exist. (Copyright © 2021, Proskuriakova et al.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu